Prognostic value of baseline genetic features and newly identified TP53 mutations in advanced breast cancer
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Oncology"
DOI: 10.1002/1878-0261.13297
Abstract: Approximately 30% of breast cancer (BC) patients suffer from disease relapse after definitive treatment. Monitoring BC at baseline and disease progression using comprehensive genomic profiling would facilitate the prediction of prognosis. We retrospectively studied 101… read more here.
Keywords: baseline; tp53 mutations; advanced breast; breast cancer ... See more keywords
Disruption of tp53 leads to cutaneous nevus and melanoma formation in Xenopus tropicalis
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Oncology"
DOI: 10.1002/1878-0261.13301
Abstract: In humans, germline TP53 mutations predispose carriers to a wide spectrum of cancers, which is known as Li–Fraumeni syndrome (LFS). To date, the association of melanomas with LFS remains unestablished. No melanomas have been reported… read more here.
Keywords: disruption; xenopus tropicalis; tp53; lfs ... See more keywords
TP53 inhibitor PFTα increases the sensitivity of arsenic trioxide in TP53 wildtype tumor cells
Sign Up to like & getrecommendations! Published in 2022 at "FEBS Open Bio"
DOI: 10.1002/2211-5463.13366
Abstract: Arsenic trioxide (ATO) has been shown to be effective in treating acute promyelocytic leukemia. TP53 mutated/null tumor cells are more sensitive to ATO treatment compared to tumor cells carrying wildtype TP53 gene copies. However, it… read more here.
Keywords: pft; tumor cells; tp53; tp53 wildtype ... See more keywords
TP53‐altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor‐based therapy: A retrospective analysis
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26595
Abstract: Long‐term follow up of prospective studies has shown that continuous Bruton's tyrosine kinase inhibitor (BTKi) therapy leads to durable remissions in previously untreated patients with TP53‐altered chronic lymphocytic leukemia (CLL); however, it is unknown how… read more here.
Keywords: tp53 altered; bruton tyrosine; inhibitor; kinase inhibitor ... See more keywords
TP53 mediated miR‐3647‐5p prevents progression of cervical carcinoma by targeting AGR2
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Medicine"
DOI: 10.1002/cam4.2507
Abstract: Previous studies have shown that miRNAs involved in a number of biological processes, such as cell growth, development, differentiation, and apoptosis. The dysregulation of miRNA expression is associated with various diseases, including cervical cancer. However,… read more here.
Keywords: mir 3647; cervical cancer; targeting agr2; cancer ... See more keywords
Mutation patterns and evolutionary action score of TP53 enable identification of a patient population with poor prognosis in advanced non‐small cell lung cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5447
Abstract: TP53 mutations are frequent in non‐small cell lung cancer (NSCLC). Different categories of TP53 mutations may be associated with survival in advanced NSCLC, but their effect on prognosis is diverse. To date, a comprehensive comparison… read more here.
Keywords: lung cancer; non small; small cell; tp53 ... See more keywords
What 20 years of research has taught us about the TP53 p.R337H mutation
Sign Up to like & getrecommendations! Published in 2020 at "Cancer"
DOI: 10.1002/cncr.33143
Abstract: The p53 tumor suppressor transcriptionally regulates a myriad of genes involved in cell cycle control, DNA repair, cell survival, and cell metabolism and represents one of the most well‐studied inhibitors of tumorigenesis. Since the discovery… read more here.
Keywords: cancer; r337h mutation; tp53 r337h; tp53 ... See more keywords
Whole‐body MRI surveillance in TP53 carriers is perceived as beneficial with no increase in cancer worry regardless of previous cancer: Data from the Swedish TP53 Study
Sign Up to like & getrecommendations! Published in 2023 at "Cancer"
DOI: 10.1002/cncr.34631
Abstract: To evaluate the psychosocial consequences of surveillance with whole‐body MRI (WB‐MRI) in individuals with the heritable TP53‐related cancer (hTP53rc) syndrome, also known as the Li‐Fraumeni syndrome, with regard to cancer worry, perceived benefits and risks… read more here.
Keywords: body mri; whole body; surveillance; tp53 ... See more keywords
Hypoxia and hyperoxia differentially control proliferation of rat neural crest stem cells via distinct regulatory pathways of the HIF1α–CXCR4 and TP53–TPM1 proteins
Sign Up to like & getrecommendations! Published in 2017 at "Developmental Dynamics"
DOI: 10.1002/dvdy.24481
Abstract: Background: Neural crest stem cells (NCSCs) are a population of adult multipotent stem cells. We are interested in studying whether oxygen tensions affect the capability of NCSCs to self‐renew and repair damaged tissues. NCSCs extracted… read more here.
Keywords: proliferation; tpm1; stem cells; rat ... See more keywords
TP53 R249S mutation in hepatic organoids captures the predisposing cancer risk.
Sign Up to like & getrecommendations! Published in 2022 at "Hepatology"
DOI: 10.1002/hep.32802
Abstract: BACKGROUND AND AIMS Major genomic drivers of hepatocellular carcinoma (HCC) are nowadays well recognized, although models to establish their roles in human HCC initiation remain scarce. Here, we used human liver organoids in experimental systems to… read more here.
Keywords: r249s mutation; hcc; liver organoids; tp53 ... See more keywords
The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective study
Sign Up to like & getrecommendations! Published in 2022 at "Hematological Oncology"
DOI: 10.1002/hon.3063
Abstract: Chronic lymphocytic leukemia (CLL) is a hematological disorder with complex clinical and biological behavior. TP53 mutational status and cytogenetic assessment of the deletion of the corresponding locus (17p13.1) are considered the most relevant biomarkers associated… read more here.
Keywords: lymphocytic leukemia; subclonal tp53; tp53 mutations; tp53 ... See more keywords